Clopidogrel Genetic Absorption Activation Panel regulatory update

Transgenomic said it received Medicare coverage for its Clopidogrel Genetic Absorption Activation Panel as an aid to predict a patient's response to cardiovascular drug Plavix clopidogrel. The test detects deficiencies associated with genes CYP2C19 and ABCB1, which are responsible for absorbing and activating the drug. Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.) and Sanofi (Euronext:SAN; NYSE:SNY, Paris, France) co-market Plavix, an adenosine diphosphate (ADP) receptor (P2Y12) antagonist. Transgenomic launched the test in November (see BioCentury, Nov. 21, 2011). ...